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Background: Non alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the United
States and worldwide. Our studies have previously shown an increase in metastatic burden in steatotic vs. normal
livers using a mouse model of diet induced steatosis. In the present study we aim to identify and evaluate the
molecular factors responsible for this increase in tumor burden.
Methods: We assessed changes in expression of a panel of matrix metalloproteinases (MMPs) using qRT-PCR
between normal and steatotic livers and validated them with western blot analysis of protein levels. To evaluate the
role of MMP13 on tumor development, we utilized a splenic injection model of liver metastasis in Wildtype and
Mmp13 deficient mice, using either parental or stable Mmp13 knockdown cell lines. Further, to evaluate changes in
the ability of tumor cells to extravasate we utilized whole organ confocal microscopy to identify individual tumor
cells relative to the vasculature. MTT, migration and invasion assays were performed to evaluate the role of tumor
derived MMP13 on hallmarks of cancer in vitro.
Results: We found that MMP13 was significantly upregulated in the steatotic liver both in mice as well as human
patients with NAFLD. We showed a decrease in metastatic tumor burden in Mmp13−/− mice compared to wildtype
mice, explained in part by a reduction in the number of tumor cells extravasating from the hepatic vasculature in
the Mmp13−/− mice compared to wildtype mice. Additionally, loss of tumor derived MMP13 through stable
knockdown in tumor cell lines lead to decreased migratory and invasive properties in vitro and metastatic burden
in vivo.
Conclusions: This study demonstrates that stromal as well as tumor derived MMP13 contribute to tumor cell
extravasation and establishment of metastases in the liver microenvironment.
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The obesity epidemic has been closely linked with an in-
creased incidence of non alcoholic fatty liver disease
(NAFLD) [1]. NAFLD results from accumulation of fat
in the liver which alters the local liver microenvironment
leading to changes in lipid profiles, recruitment of in-
flammatory cells and changes in cytokine expression* Correspondence: lee.gorden@vanderbilt.edu
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unless otherwise stated.[2,3]. The changes in the tissue microenvironment can
affect cell-cell interactions and influence the develop-
ment of both primary and metastatic tumors. Epidemio-
logical studies show that NAFLD has been linked to an
increase in the risk for development of primary liver
cancer [4,5] but very little is known about the effect of
steatosis on tumor metastasis to the liver. The liver is a
frequent site of metastasis for several cancers such as
colorectal cancer, breast and pancreatic cancer. In
addition, obesity is an independent risk factor for the de-
velopment of these tumor types among others [6]. Pre-
vious studies from our lab have shown that mice withtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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static burden compared to mice with normal livers [7].
Metastasis represents the end-stage of cancer progres-
sion and is responsible for most cancer related deaths
[8]. Improved understanding of the metastatic tumor
microenvironment is important in devising therapies to
impact this stage of the disease.
Matrix metalloproteinases (MMPs) are a family of zinc
dependent proteases that are capable of cleaving various
components of the extracellular matrix. Apart from
matrix molecules, they can also cleave adhesion proteins,
activate growth factors such as TGF-β and VEGF as well
as release and activate cytokines [9,10]. MMPs are pro-
duced by tumor cells, stromal cells and infiltrating in-
flammatory cells and facilitate host-tumor interactions.
Members of the MMP family have been associated with
progression through multiple stages of cancer, from ini-
tiation to acquisition of metastatic properties [11,12].
However, MMPs have also been shown to have anti-
tumorigenic functions and are important for normal de-
velopmental and wound healing responses [13]. Early
clinical trials broadly targeting the MMP family as a
whole, led to unintended clinical side effects. Improved
understanding of specific roles for individual MMPs and
development of pharmaceutical agents that selectively
target individual MMPs may be part of effective thera-
peutic strategies in the future [14].
MMP13 is an interstitial collagenase that is capable of
cleaving multiple collagens, preferentially collagen II, as
well as other matrix substrates such as gelatin, fibronec-
tin, and aggrecan relevant to tumor metastasis [15]. This
protease has been previously linked to the progression
of fibrotic liver disease [16]. In addition, increased ex-
pression of MMP13 has been associated with poor prog-
nosis in patients with colorectal cancer metastasis to the
liver [17]. MMP13 was identified as a part of the breast
cancer metastasis signature and was associated with de-
creased overall survival and metastasis in breast cancer
and renal cell carcinoma [18-20]. Furthermore, stroma-
derived MMP13 was found to be involved in the growth
of liver, lung, brain and heart metastases of melanoma
cells [21]. We thus hypothesize that both stromal and
tumor derived MMP13 play an important role in modu-
lating the liver microenvironment and facilitate the es-
tablishment of liver metastasis.
Results
MMP13 expression is elevated in the steatotic liver
Previous studies in our lab have found a significant in-
crease in the metastatic tumor burden to the liver in the
setting of steatosis as compared to normal mouse livers
[7]. Additionally, our group has identified MMP9 as an
important mediator of tumor metastasis to the liver [22]
and other groups have shown several additional MMPsto be important in metastasis [23]. With the increasing
recognition of NAFLD as a significant liver disease, it is
highly relevant to understand which MMPs are altered
in the steatotic microenvironment and whether these
MMPs contribute to the increased metastasis. We as-
sessed the relative gene expression levels of a panel of
MMPs, associated with tumor progression, in the liver
tissue of mice with steatosis compared to normal mice
(n = 3). We found that Mmp12 (P < 0.001) and Mmp13
(P < 0.05) were significantly upregulated in the liver of
mice with steatosis compared to normal livers using
2-way ANOVA followed by the Bonferroni post-test
(Figure 1a). Both Mmp12 and Mmp13 have been re-
cently shown to be elevated in the liver in other models
of diet induced obesity as well [24]. MMP13 has previ-
ously been associated with fibrotic liver disease [16] and
its expression in tumors has been associated with poor
prognosis in patients with colorectal cancer metastasis
to the liver [17]. MMP13 protein levels were evaluated
in the mouse liver and were found to be increased in
the steatotic livers compared to normal livers (n = 9,
P = 0.04, using the 2-tailed t-test)(Figure 1b). To deter-
mine whether changes in MMP13 levels were relevant to
the human progression of NAFLD, we evaluated the
MMP13 protein levels by western analysis from liver ly-
sates of normal livers and compared them to livers with
steatosis, steatohepatitis or NAFLD related cirrhosis.
Figure 1c shows that MMP13 protein expression is in-
creased with NAFLD (P < 0.05, n = 9 per group, using
2-tailed t-test compared to normal livers). No significant
differences were observed between the different stages
of NAFLD. Immunohistochemical analysis of MMP13
expression shows staining of MMP13 with steatosis in
the murine liver (Figure 1d) and varied distribution of
the protein in both stromal cells as well as hepatocytes
in human patient samples with NAFLD (Figure 1e).
Thus, MMP13 is elevated both in human NAFLD as
well as in a mouse model of diet induced steatosis.
Loss of host derived MMP13 leads to decreased tumor
metastasis to the liver
Elevation of MMP13 in the steatotic liver suggested that
it could play an important role in priming the steatotic
liver microenvironment for tumor establishment. To
elucidate the role of host MMP13 on tumor metastasis
to the liver, Mmp13 null (Mmp13−/−) mice were fed a
high fat diet to induce steatosis. Mmp13−/− mice devel-
oped steatosis comparable to the wildtype counterparts
(Additional file 1: Figure S1). Subsequently, wildtype and
Mmp13−/− mice with and without steatosis were inocu-
lated with 5 × 105 syngeneic MC38 colon cancer cells
through the intrasplenic/portal route to generate experi-
mental liver metastases. After 2 weeks, mice were sacri-
ficed and livers were harvested. The liver weight and
Figure 1 (See legend on next page.)
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Figure 1 MMP13 is elevated in the steatotic liver. (a) Relative gene expression of matrix metalloproteinases (MMPs) in liver tissue of mice
with steatosis (black bars) compared to normal (white bars) mice. Transcript levels were normalized to GAPDH and expressed as fold change
relative to normal controls. Values represent the mean (n = 3 per group). Statistical analysis was carried out using 2-way ANOVA followed by
Bonferroni post test between normal and steatotic samples for each MMP tested. (b) Representative western blot showing 3 samples per group and
densitometric quantification (n = 9 per group) of MMP13 protein levels relative to actin levels in livers of wildtype C57bl/6 mice with and without
steatosis. Statistical analysis was carried out using a 2-tailed t-test, P = 0.04. (c) Representative western blot and densitometric quantification of MMP13
protein levels relative to actin levels in human liver samples through multiple stages of NAFLD (n = 9 per group). Statistical analysis was carried out
using a 2-tailed t-test with respect to normal livers. No significant differences were observed between the different stages of progression of NAFLD.
(d) Representative immunohistochemical (IHC) staining of MMP13 in murine normal and steatotic livers. Inset represents IgG control. (e) Representative
IHC of human MMP13 at different stages of NAFLD. MMP13 staining is detected at low levels in the normal liver hepatocytes and is increased in the
stromal cells of livers with steatosis and steatohepatitis. Additionally, MMP13 is present in select hepatocytes in cirrhotic livers. Images were taken at
20X, Scalebar represents 100 microns.
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measured to determine metastatic burden (Figure 2b, c),
and livers were fixed, dissected and stained by H&E
(Figure 2a) to record the incidence (Figure 2d) and area
(Figure 2e) of metastases. Tumor burden and incidence
of metastases increased in the steatotic compared with
normal mice in both the wildtype and Mmp13−/− mice.
However, the tumor burden, incidence and area of liver
metastases was markedly reduced in the Mmp13−/−
mice compared to the wildtype mice after tumor cell in-
jection, thus supporting the role of MMP13 in meta-
static tumor growth to the liver both in normal and
steatotic mice. Statistical analysis was carried out by
one-way ANOVA followed by Newman-Keuls multipleFigure 2 Loss of host derived MMP13 leads to decreased tumor meta
Haematoxylin & Eosin of wildtype and MMP13−/− mice with normal or ste
compared to MMP13−/− mice (n = 5). Tumors are denoted by black dashe
(c) tumor burden measured as percent liver weight to total body weight, me
area per liver section in normal and steatotic livers. Statistical analysis was per
one-way ANOVA followed by Newman-Keuls Multiple Comparison Test. P valcomparison test. P values are represented by stars where:
* ≤ .05, ** ≤ .01, and *** ≤ .001 (Figure 2).
Additionally, liver metastases were stained for Ki67
(proliferation marker) and cleaved caspase-3 (apoptosis
marker) to further examine the role of MMP13 in
promoting the proliferation and outgrowth of metastatic
tumors (Additional file 1: Figure S2). Using one-way
ANOVA analysis, no significant differences were observed
in the percentage of tumor cells proliferating or undergo-
ing apoptosis between the wildtype and Mmp13−/−
tumors of comparable size suggesting no difference in the
rate of tumor growth between the WT and Mmp13−/−
mice. Additionally, there was no significant difference
in tumor vascularity as determined by vWF stainingstasis to the liver. (a) Representative liver cross sections stained with
atotic livers show an increased tumor burden in wildtype mice
d line. Quantification of metastatic tumor burden by (b) liver weight,
tastatic seeding by quantification of (d) tumor number and (e) tumor
formed using GraphPad Prism software. Data was analyzed by using
ues are represented by stars where: *≤ .05, **≤ .01, and ***≤ .001.
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were changes in tumor outgrowth, a histogram of tumor
size distribution were plotted (Additional file 1: Figure S3).
Mmp13−/− mice had fewer tumors and the distribution
curve shifted to the left compared to WT mice, however
the tumors were still capable of becoming large, suggesting
that loss of host MMP13 could affect some of the earlier
steps in the metastatic cascade such as tumor cell survival
in the vasculature and seeding to the liver or ability of
tumor cells to adhere to the vasculature and extravasate
into the liver tissue.
Loss of host MMP13 affects the ability of tumor cells to
extravasate
Since we observed a decrease in tumor burden with the
loss of MMP13 in both normal and steatotic mice, we
focused on the role of MMP13 on tumor metastasis to
the liver irrespective of the diet. To determine whether
the decrease in tumor burden in the Mmp13−/− mice
compared to wildtype mice resulted from a difference in
the ability of the tumor cells to survive in circulation
and seed the liver, we injected normal wildtype orFigure 3 Lack of stromal MMP13 leads to decreased tumor cell extrav
the liver at 24 and 48 hours post intrasplenic injection of MC38 tumor cells
field from 5 random images per mouse (n = 3). (b) Quantification of the pe
post injection of wildtype and MMP13−/− mice (n = 3). Statistical analysis w
reconstruction of wildtype and MMP13−/− hepatic vasculature and (d) qua
mice (n = 5). Statistical analysis was performed using the 2-tailed t-test.Mmp13−/− mice with 1 × 106 MC38 tumor cells, labeled
with cell tracker red, and sacrificed the mice 24
and 48 hours post injection. Livers were harvested,
processed, sectioned and the number of tumor cells per
section were quantified (Figure 3a). These results de-
monstrate no significant differences in the number of
tumor cells present in the livers of these mice of wild-
type and Mmp13−/− mice at 24 (P = 0.2) and 48 (P = 0.4)
hours post injection and therefore no difference in sur-
vival or seeding of the cells to the liver using the two-
tailed student t test.
To investigate the role of host MMP13 on the ability of
MC38 colon cancer cells to extravasate from the
vasculature, we adapted the methodology developed by
Martin et al. [25]. MC38 cells were labeled with cell tracker
red and injected into normal wildtype or Mmp13−/− mice.
Mice were sacrificed at 24 and 48 hours post injection,
their livers perfused with saline and their vasculature
labeled with tomato lectin. The liver explants were then
imaged using a confocal microscope to visualize individual
tumor cells relative to the vasculature and compare
the percentage of tumor cells that had extravasated inasation from the microvasculature. (a) Number of tumor cells in
quantified as average number of cell tracker red labeled cells per 10X
rcentage of tumor cells extravasating in the liver at 24 and 48 hours
as performed using the 2-tailed t-test. (c) Representative image of 3D
ntification of hepatic vascular volume in wildtype and MMP13−/−
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observed a decrease in the percentage of tumor cells that
had extravasated in the MMP13−/− mice compared to
that of the wildtype mice which was not significant at
24 hours (P = 0.06 using 2-tailed t-test) but became signifi-
cant at 48 hours(P = 0.02 using 2-tailed t-test) post tumor
cell injection (Figure 3b).
The hepatic vascular volume was evaluated from the
3-D vascular reconstructions (Figure 3c, d) of wildtype
and Mmp13−/− mice liver. No difference in quantity of
vascular staining was observed between the wildtype and
Mmp13−/− mice indicating that changes in extravasa-
tion do not result from changes to the vascular capacity
(P = 0.7 using 2-tailed t-test).
Loss of tumor derived MMP13 leads to decrease in
migratory and invasive properties of cells in vitro
MMP13 is a part of the breast cancer metastasis signa-
ture and tumor cell expression of MMP13 is linked with
increased invasiveness and ability to metastasize in mel-
anoma and breast cancer [18,21]. Immunohistochemical
analysis of murine experimental MC38 colon carcinoma
tumors in the liver and human colorectal cancer me-
tastases to the liver show MMP13 staining within these
tumors (Figure 4a, b). We evaluated Mmp13 gene ex-
pression in murine and human colorectal cancer cell
lines and found that Mmp13 is expressed by the MC38
(murine) and HCT116 (human) colorectal cancer cell
lines. To assess the role of tumor derived MMP13 on
the ability of tumor cells to metastasize to the liver, we
developed MMP13 stable knockdown cell lines (Additional
file 1: Figure S4) using RNA interference. In vitro, knock-
down of Mmp13 does not have a significant effect on cell
proliferation as determined by the MTTassay in the MC38
nor the HCT116 cell line (Figure 4c, f). To study the effect
of MMP13 on cell migration, control and Mmp13 knock-
down cells were seeded in a modified Boyden chamber.
Both MC38 and HCT116 cell lines showed a decrease in
transwell migration compared with the respective control
cells (Figure 4d, g). Next, the knockdown cell lines were
evaluated for their ability to invade through matrigel with
the modified Boyden chamber and demonstrated a de-
creased invasive ability with the knockdown of Mmp13 in
both cell lines (Figure 4e, h). Data was analyzed by using
one-way ANOVA followed by Newman-Keuls multiple
comparison test. P values are represented by stars where:
*** P ≤ 0.0001 when compared to the respective non-
silencing control treated cell lines. For the HCT116 cell
line, there was an average 9 fold decrease in transwell inva-
sive ability between the knockdown cell lines and controls,
and a 2.5 fold decrease in transwell migration, suggesting
loss of MMP13 effects cell invasion in addition to its effect
on cell migration. These results suggest that tumor derived
MMP13 is essential for migration as well as invasion.Loss of tumor derived MMP13 reduces the ability of
tumor cells to metastasize in vivo
To test the importance of tumor cell derived MMP13 on
establishment of metastasis to the liver, we utilized the
splenic injection model to deliver 2.5 × 105 Mmp13
knockdown or control MC38 cell lines into wildtype
C57bl/6 mice. 21 days post injection, mice were sacri-
ficed and livers harvested. The liver weight and percent
liver weight to total body weight ratio was measured to
determine metastatic burden (Figure 5b, c). Liver sec-
tions were stained by H&E (Figure 5a) to record the in-
cidence (Figure 5c) and area (Figure 5d) of metastasis.
Overall, the tumor burden and incidence of metastases
decreased in the mice injected with Mmp13 knockdown
cells compared to control cells. Statistical analysis was
carried out by one-way ANOVA followed by Newman-
Keuls multiple comparison test. P values are represented
by stars where: * ≤ .05, ** ≤ .01, and *** ≤ .001 (Figure 5).
Liver metastases were stained for Ki67 (proliferation
marker) and cleaved caspase-3 (apoptosis marker) to
examine the role of MMP13 in promoting the survival
and outgrowth of metastatic tumors (Additional file 1:
Figure S5). The percentage of tumor cells proliferating
or undergoing apoptosis were similar between the wild-
type and Mmp13−/− tumors of comparable size sugges-
ting no difference in the rate of tumor growth between
the WT and Mmp13−/− mice. Additionally, there was
no difference in tumor vascularity as determined by
vWF staining (Additional file 1: Figure S5). These results
suggest that tumor derived MMP13 facilitates the estab-
lishment of metastases in the liver without affecting
metastatic outgrowth.
Discussion
The liver is a common site of metastasis for several types
of cancer [26] and identification of molecular effectors
that can prevent metastasis to the liver is of important
clinical relevance. NAFLD is increasingly becoming rec-
ognized as the most common cause of liver disease and
it is associated with increased risk of development of pri-
mary liver cancers, even prior to establishment of cirrho-
sis [1]. Progression of NAFLD results in changes in the
liver microenvironment and alterations in the extracel-
lular matrix, which effects cancer progression and out-
come [27,28]. The MMPs are an important class of
proteases that can alter the extracellular matrix and
influence the microenvironmental integrity. There is
considerable evidence supporting the role they play at
different steps of malignant tumor metastasis including
tumor cell intravasation and extravasation [29]. We ini-
tially evaluated the steatotic microenvironment for alter-
ations in the gene expression levels for a panel of MMPs
that have been previously associated with cancer pro-
gression. Our results demonstrate that MMP13, an
Figure 4 (See legend on next page.)
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Figure 4 Effect of knockdown of MMP13 in tumor cells on various hallmarks of cancer in vitro. Immunohistochemical staining for MMP13
in representative sections of (a) murine MC38 tumor in the mouse liver and (b) human colorectal cancer metastasis to the liver at 20X magnification.
Scalebar represents 100 microns. Inset shows individual tumor cells at 63X magnification. MTT assay shows no change in proliferation after loss of
MMP13 in vitro in (c) MC38 or (f) HCT116; control and MMP13 knockdown cell lines. Knockdown of MMP13 leads to decreased ability of tumor cells to
migrate in vitro as determined by a transwell migration assay in (d) MC38 and (g) HCT116 cell lines. Knockdown of MMP13 leads to decreased ability
of tumor cells to invade in vitro as determined by the transwell invasion assay in (e) MC38 and (h) HCT116 control and knockdown cell lines. Statistical
analysis was performed using GraphPad Prism software. Data was analyzed by using one-way ANOVA followed by Newman-Keuls Multiple Comparison
Test. P values are represented by stars where: *** P≤ 0.0001 when compared to the respective non-silencing control treated cell lines.
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our murine model as well as in human patient samples
with NAFLD. Other groups have additionally shown that
MMP13 is elevated in fibrotic liver disease [16] and
could be relevant in other settings such as hepatitis as
well. Several studies also link elevated levels of MMP13 in
either the stroma or tumor cells with cancer progression
[17,18,20,21], however there are reports that alternately
suggest a protective role for MMP13 [30,31]. There still
remains a limited understanding of the role of MMP13 in
the liver microenvironment and its influence on the estab-
lishment of hepatic metastases. Here, we evaluated the
role of both stromal and tumor cell derived MMP13 on
the establishment of metastases in the liver.Figure 5 Knockdown of tumor derived MMP13 leads to decreased tu
stained with Haematoxylin & Eosin of wildtype mice injected with control o
MSh13-2). Dashed black lines denote tumors. Quantification of metastatic t
percent liver weight to total body weight, (d) metastatic seeding by quant
liver area in normal and steatotic livers (n = 5 per group). Statistical analysis
using one-way ANOVA followed by Newman-Keuls Multiple Comparison Te
***≤ .001 when compared to mice injected with non-silencing control cellUsing mice genetically deficient in MMP13 we have
shown that loss of stromal MMP13 leads to a significant
decrease in the tumor burden in the liver. This effect
was seen in both normal and steatotic livers, suggesting
that elevation of MMP13 in the liver plays a role in
tumor metastasis. Although we saw a significant de-
crease in tumor burden in the Mmp13 deficient mice,
differences in proliferation or apoptosis were not ob-
served within the tumors, nor were any differences in
the vascularity of the tumors. This suggested that the
difference in metastatic burden was due to early events
in the metastatic cascade. Similar levels of metastatic cell
dissemination and early cell survival were observed in
wildtype compared to Mmp13 deficient livers, yet themor metastasis to the liver. (a) Representative liver cross sections
r MMP13 knockdown MC38 cell lines (MSh13 pooled, MSh13-1, and
umor burden measured by (b) liver weight, (c) tumor burden as a
ification of tumor number and (e) percentage of tumor area to total
was performed using GraphPad Prism software. Data was analyzed by
st. P values are represented by stars where: * ≤ .05, ** ≤ .01, and
lines.
Mendonsa et al. Molecular Cancer  (2015) 14:49 Page 9 of 12loss of host MMP13 diminished the ability of tumor
cells to extravasate. Several factors can influence the
ability of tumor cells to adhere to the vascular walls and
extravasate into the surrounding tissues. Studies have
shown that changes in expression level and structure of
collagen surrounding the vasculature are important in
the ability of tumor cells to extravasate [31-33]. Since
MMP13 is a collagenase, we evaluated the level of
collagen I, II and IV in the liver but found that mice
lacking MMP13 had no significant differences in colla-
gen mRNA expression and immunofluorescence staining
pattern compared to the wildtype mice. Further, we did
not observe any differences in fibrotic disease progres-
sion as shown by trichrome staining of murine liver sec-
tions (Additional file 1: Figure S6).
Although we did not observe changes in collagen in
the liver, MMP13 may mediate release or activation of
critical factors involved in tumor cell extravasation.
MMP13 can cleave, release and activate cytokines
thereby altering recruitment and or activation of inflam-
matory cells such as neutrophils and macrophages that
have been shown to facilitate tumor cell extravasation
[34-37]. We evaluated changes in the lymphoid and
myeloid lineage inflammatory cell sub populations
within the liver of wildtype and Mmp13−/− mice but did
not see significant differences within the inflammatory
cell subpopulations. However, the activation state and
function of the immune cells could alternately explain
the differences in tumor burden observed without being
reflected in absolute cell numbers.
MMP13 expression has been observed in invasive ma-
lignant tumors such as breast carcinomas, squamous cell
carcinomas (SCCs) of the head and neck and vulva, pri-
mary and metastatic melanomas, hepatocellular carcin-
oma cell lines [38] and transitional cell carcinoma of the
urinary bladder [39]. Colorectal cancers can be classified
as either the most commonly seen classical nonmu-
cinous adenocarcinomas (AC) or as the less frequent
subtypes of mucinous adenocarcinomas (MAC) and
signet-ring cell carcinomas (SC) [40]. Recent studies
showed that the nonmucinous ACs had a higher tumor
derived MMP13 protein levels than MACs and SCs,
which are more invasive and have a higher frequency of
lymph node metastasis than nonmucinous ACs [41].
MACs and SCs have different characteristics from clas-
sical ACs and might have additional mutational changes
that circumvent the requirement of MMP13 and affect
their ability to invade and metastasize [40]. Further,
levels of related MMPs including MMP1, MMP8,
MMP14, MMP2 and MMP9 which have previously been
shown to affect tumor cell invasion were not evaluated
in these studies and could compensate for MMP13 levels
[42]. Our results indicate that both the MC38 murine
colon cancer line and the HCT116 colon cancer cellsexpress MMP13. Knockdown of Mmp13 utilizing lenti-
viral shRNA resulted in a decreased ability of tumor cells
to migrate and invade in vitro and correspondingly led
to the development of fewer metastasis in vivo. Coupled
together, both tumor cell and host derived MMP13 pro-
mote the establishment of metastases in the liver.
The use of selective MMP13 inhibitors may be an im-
portant step to control tumor growth and metastasis to
the liver, however in the past, the clinical use of MMP
inhibitors has been hampered by their lack of specificity
[43]. Fortunately, progress is being made toward deve-
loping specific inhibitors and a few MMP13 selective in-
hibitors are currently being studied [19,44]. MMP13 is
an ideal candidate with relatively low expression in nor-
mal adult tissues that will limit unwanted side effects
when targeted [15]. It will therefore be important to
determine whether MMP13 selective inhibitors can
pharmacologically block metastasis to the liver.
Conclusions
In conclusion, we have shown that MMP13 is elevated
in the setting of hepatic steatosis and that both tumor
and stromal derived MMP13 are involved in attenuating
metastatic tumor burden in the liver. Collectively, these
data suggest that MMP13 could represent a new the-




Liver biopsies from consented patients undergoing bar-
iatric surgery were collected and flash frozen for protein
or RNA collection and further de-identified in accord-
ance with a protocol approved by Vanderbilt’s Internal
Review Board (VUMC IRB#120829). Samples were re-
viewed by aVanderbilt University pathologist and classified
as either Normal (<5% Steatosis), Steatosis, Steatohepatitis
or NAFLD related cirrhosis based on histology. De-
identified formalin-fixed, paraffin-embedded liver tissue
sections from patients with colorectal cancer metastasis to
the liver were obtained from the Vanderbilt Translational
Pathology Shared Resource.
Mice
8 week old C57bl/6 J male mice were obtained from
Jackson Research Laboratories (Bar Harbor, ME) and
a breeding pair of MMP13 null mice was obtained
(Laboratory of Dr. Zena Werb, UCSF). Mice were housed
in a level 6 animal facility at Vanderbilt University. Mice
were fed either regular chow, a 13.5% fat diet (5001,
LabDiet) or fed a 42% calories from fat diet (TD.88137,
Harlan Teklad) ad libitum for 3 months at which time
point we have shown that wildtype mice develop pro-
minent steatosis [7].
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MC38 murine colon cancer cells lines, syngeneic to
C57Bl/6 background were provided by Dr. Steven
Libutti, NCI. HCT116 human colorectal carcinoma cell
line was obtained from ATCC (CCL-247). Cell lines were
grown in culture conditions of 10% fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA) in Dulbecco’s
Modified Eagle Media (Gibco BRL, Carlsbad, CA) at
37°C and 5% CO2, and harvested at 75% confluence for
experimental studies.
Western blot
Protein lysates were prepared with RIPA lysis buffer.
Protein concentration was determined by the Pierce
BCA protein assay (Thermo Scientific). 30 μg of protein
was loaded into each well and separated on a 10% SDS-
PAGE gel. Proteins were transferred onto a nitrocellu-
lose membrane, subsequently blocked with 3% milk, and
then incubated with anti MMP13 antibody (Abcam,
ab39012) overnight at 4°C. The blots were washed and
then incubated with secondary antibody (IR700 con-
jugated donkey anti rabbit IgG) for 1 h at room tem-
perature. Blots were washed and then imaged with Licor
Odyssey scanner.
qRT-PCR
RNA was extracted using a combined Qiazol extraction
and subsequent Qiagen RNeasy mini kit. One micro-
gram of total RNA was reverse transcribed using the
high capacity cDNA reverse transcription kit (Applied
Biosystems) and real-time PCR was performed using
specific primers for mouse MMPs with GAPDH as con-
trol (Qiagen, QT00116116, QT00107751, QT00110012,
QT00113540, QT00108815, QT00115521, QT00099729,
QT01658692, QT00098945, QT01064308). Real-time
PCR was performed with the iQ SYBR green supermix
kit (Bio-Rad) according to the manufacturer’s ins-
tructions and measured via a CFX96 real time PCR de-
tection system (Bio-Rad). Experiments were done in
triplicate with three replicates per sample. Fold-change
was determined relative to normal wildtype samples and
calculated using GAPDH levels as a reference.
Histology and immunohistochemistry
Liver tissue was formalin fixed, embedded in paraffin
blocks, and cut into 6 μm sections. For histology, sections
were rehydrated with xylenes and a decreasing ethanol
series and then stained with Mayer’s Hematoxylin (Sigma)
and Eosin. Hydrated sections were boiled in a citric acid
solution (10 mM trisodium salt dihydrate pH 6.0, 0.5%
Tween-20) for 8 minutes to unmask antigen. Slides were
stained with primary antibody (MMP13: sc-12363, Ki67:
ab15580, Cleaved caspase 3: cell signaling D175, vWF:
Dako A0082) and incubated overnight at 4°C, washed andincubated with biotinylated secondary antibody (Vector
Labs), processed with the ABC Vectastain kit (Vector
Labs) and developed in chromogen solution (0.1 M Tris–
HCl pH 7.4, 1.125 mM diaminobenzidine, 0.01% H2O2).
Slides were counterstained with Mayer’s Hematoxylin
Solution (Sigma), dehydrated with ethanols and mounted
with permount. Slides were imaged with a Q Imaging
Micropublisher color digital camera mounted to a Zeiss
Axioplan 2 microscope using MetaMorph software for
acquisition.
Experimental liver metastasis
Experimental liver metastasis was carried out as pre-
viously described [7]. Briefly, 5-month-old wildtype or
Mmp13 knockout mice that had been on diet for
3 months were injected with 5 × 105 MC38 parental or
Mmp13 knockdown cells into the spleen and allowed to
perfuse to the liver for 3 minutes before splenectomy.
Mice were maintained on respective diets and sacrificed
14 days post-injection. At the time of sacrifice the mice
were weighed, the livers were removed and weighed, and
the livers were processed for histology as described
above. Graphical representation of metastatic burden
was calculated using GraphPad software to compare
total liver weights and percent liver weight relative to
total animal weight. Further, in-depth quantitative ana-
lysis of tumor burden was assessed on the left lateral
lobe of the liver, that was fixed and cut sagittally into
four parts, paraffin-embedded, sectioned and stained for
H&E. Slides were scanned at 20X using an Ariol® SL-50
scanner. Ariol software was used to quantify the size and
number of tumors per section.
Tumor cell extravasation
To determine the number of tumor cells extravasating
in the liver, we utilized the methodology previously de-
scribed by Martin et al. [25], with some modifications.
Briefly, mice were injected intrasplenically with 1×106
cell tracker red (Life Technologies) labeled MC38 tumor
cells. At 24 and 48 hours post injection, mice were
anesthetized using isoflurane and placed on mechanical
ventilation at 60 breaths/minute through surgical tra-
cheostomy. 100 μl of 0.5 mg/ml 488-tomato lectin vascu-
lar label (Vector Laboratories, DL-1174) was injected into
the spleen and allowed to circulate throughout the body
for 6 minutes. Next, the abdominal aorta was cut to
provide outflow and livers were perfused with PBS using
gravity pressure through the heart and spleen. After the
effluent had cleared, the liver was resected en-bloc, placed
in a glass bottom dish with #1.5 glass (In Vitro Scientific)
and immediately imaged.
Images were acquired with a LSM780 confocal micro-
scope (Carl Zeiss Inc.) using a Fluar 40X oil objective with
NA = 1.30 at room temperature. 488 nm and 561 nm laser
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the vasculature cell tracker labeled tumor cells. The band-
pass emission filters for the two channels were set as
follows: 499 – 552 nm for the green fluorescence, and
602 – 747 nm for the red fluorescence. The pixel size was
set to 0.692 μm and the dwell time was 12.6 μs. Images
were acquired every 0.700 μm for every z-stack. The laser
power of the laser lines was independently adjusted for
each stack, between 0.1% and 3%, to avoid saturated pixels
and to maintain a good signal to noise ratio through all
the planes. The bit depth of the images was set to 12 bit.
Image analysis was performed using Fiji [45]. The tridi-
mensional structure of the vasculature was reconstructed
from each z-stack using the Tubeness function [46] and
overlaid onto the red channel to identify a cell as extrava-
sating or not. Percentage of cells extravasating at each
time point was determined from over 30 individual tumor
cells per mouse (n = 3 per group).
Establishment of stable MMP13 knockdown cell lines
Pooled lentiviral particles targeting three different regions
of murine Mmp13 (Open Biosystems: V2LMM_28573,
V2LMM_ 34601, V2LMM_37490) and control particles
were used to transfect MC38 cells. Control non-target and
specific human MMP13 shRNA lentiviral particles target-
ing three different regions of human MMP13 (sc-41559)
were used to transfect HCT116 cells. Post-transfection,
shRNA-expressing cells were selected with puromycin.
Knockdown was confirmed in resulting clones with qRT-
PCR and western blot analysis.
MTT
Proliferation of cells was determined using the MTT
assay. Briefly, 10×104 cells were plated in each well of a
96 well plate and allowed to attach overnight. Cells were
serum starved for 24 hours followed by changing to
DMEM containing 10% FBS for 24 hours. 20 μl of MTT
reagent (5 mg/ml, Sigma) was added to each well and in-
cubated at 37°C for 2 hours after which the media was
aspirated and the remaining MTT formazan crystals dis-
solved in 100 μl of isopropanol. Absorbance at 570 nm
was read using a Victor3 V 1420 Multilabel Plate Coun-
ter. Experiments were carried out in triplicate with 5
replicates per plate.
Transwell migration and invasion assays
Cell migration and invasion were assessed by a modified
Boyden assay using 24 well multi-well inserts (BD) with
8 μm pore PET membrane. Mmp13 knockdown and
control MC38 or HCT116 cells (1×105 cells/chamber)
were seeded in DMEM plus 1% FBS directly on the in-
sert membrane (Migration) or resuspended in 100 μl of
1 mg/ml of basement membrane matrix (BD) (Invasion)
and seeded on the membrane. DMEM with 10% FBSwas added to the lower chamber and cells were allowed
to migrate through the filter for 16 h at 37°C in 5% CO2
for MC38 cells and 48 h for HCT116 cell lines. MC38
cells were allowed to invade for 24 h and HCT116 cells
for 72 hours. Cells on the lower surface of the mem-
brane were fixed in 100% methanol, stained with Dapi,
and imaged. Experiments were carried out in triplicate
with three replicates per experiment and the number of
cells migrated/invaded per 10X field was determined
from five random fields per well.
All animal experimental procedures and protocols
were carried out in accordance to the ARRIVE guide-
lines. Experimental procedures and protocols were ap-
proved by the Vanderbilt university medical center
IACUC protocol #M/09/216 and performed according
to the institutional ethical guidelines for animal care and
use. Human tissue samples were collected under the
National Cancer Institute (NCI) best practices and CHTN
standard operating procedures and approved by the
Vanderbilt Internal Review Board (VUMC IRB #120829).Additional file
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